Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-10-07
Butterfly Network, Inc.
Butterfly sells handheld ultrasound probes, cloud workflow software, and licensed Ultrasound-on-Chip technology to clinicians, health systems, educators, and developers.
ai hardware healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Handheld ultrasound seeks a platform second act
The upside case is not more probes alone. It is whether regulated workflow, licensing, and partner distribution turn a useful device into a broader imaging platform by 2031.

Analysis

Thesis
Butterfly can still more than double equity value by 2031 if it converts a differentiated handheld ultrasound and chip stack into a higher-value trust, workflow, and licensing platform; the non-linear upside comes from Embedded, Garden, and governed clinical software attaching to a larger installed base rather than probe volume alone.
Last Economy Alignment
Cheaper AI guidance should expand who can scan and where scans happen, while Butterfly owns a regulated probe, workflow layer, and a nascent licensing surface. The main check is that larger imaging vendors can bundle similar capabilities before Butterfly proves platform economics at scale.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.3x (from 5 most recent analyses)
Reasoning
The realistic upside is a strong device-plus-software-plus-licensing story, not a pure moonshot. Butterfly already has a real product, improving margins, and early evidence that partner revenue can be higher quality than core hardware. If it proves that enterprise workflow, partner launches, and new care settings make each deployment more valuable over time, investors can support a materially larger equity value even with a lower sales multiple than today.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is conversion, not invention. Butterfly has a working product and real gross-margin leverage, but the equity case now depends on proving that workflow, licensing, and ecosystem revenue can diversify beyond a few early wins before cash burn, regulatory timing, and incumbent bundling pull it back toward a conventional device valuation.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.45
It owns the probe, the chip, and part of the clinical workflow around handheld ultrasound, so cheaper AI should make more scans possible and make its software more useful. The risk is that bigger imaging companies bundle similar hardware and software before Butterfly proves its partner ecosystem is more than a few early wins.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$11.40
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case